United States - English - NLM (National Library of Medicine)

prokim kagitcilik ve kimyevi maddeler limited sirketi - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic • hand wipes to decrease bacteria on the skin • recommended for repeated use • for use when soap and water are not available

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

gensenta İlaÇ sanayi ve ticaret a.Ş, turkey - cabazitaxel - concentrate and solvent for solution for infusion - 60 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

nobel ilac sanayii ve ticaret a.s, turkey - desloratadine - tablet, film-coated - 5

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - control of penetration | reduce alkaline hydrolysis | wetting agent (use as directed) | improve penetrating properties

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

bilim ilac sanayi ve ticaret anonim sirketi, turkey - rosuvastatin - film coated tablet - 10 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

bilim ilac sanayi ve ticaret anonim sirketi, turkey - rosuvastatin - film coated tablet - 20 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

nobel ilac sanayii ve ticaret a.s, turkey - rosuvastatin - film coated tablet - 20mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

nobel ilac sanayii ve ticaret a.s, turkey - rosuvastatin - film coated tablet - 10 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; brilliant blue fcf; allura red ac; gelatin; phloxine b - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; calcium sulfate dihydrate; sodium bicarbonate; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.